ABX311, a novel small molecule inhibiting Chikungunya replication

ABX311 is the second molecule coming from the ABIVAX antiviral platform. ABX311 is a small molecule able to inhibit Chikungunya viral replication in vitro with an IC50 in the nanomolar range. ABX311 will enter preclinical development Q4 2016.
Chikungunya is a mosquito-borne viral disease first described during an outbreak in southern Tanzania in 1952. It is an RNA virus that belongs to the alphavirus family
Chikungunya is characterized by an abrupt onset of fever frequently accompanied by joint pain. Other common signs and symptoms include muscle pain, headache, nausea, fatigue and rash. The joint pain is often very debilitating, but usually lasts for a few days or may be prolonged to weeks. Hence the virus can cause acute, subacute or chronic disease. Most patients recover fully, but in some cases joint pain may persist for several months, or even years.

Chikungunya has been identified in over 60 countries in Asia, Africa, Europe and the Americas.

There is no specific antiviral drug treatment for chikungunya. Treatment is directed primarily at relieving the symptoms, including the joint pain using anti-pyretics, analgesics and fluids. There is no commercial chikungunya vaccine.